VISITECT® CD4 Advanced Disease evaluation

RNS Number : 8791I

Omega Diagnostics Group PLC

06 April 2020

 

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

VISITECT® CD4 Advanced Disease evaluation in

 Malawi, Zimbabwe and the Democratic Republic of Congo

Omega (AIM: ODX), the medical diagnostics company focused on CD4, food intolerance and allergy testing notes the publication on 3 April 2020 of the two phased diagnostic accuracy and feasibility-of-use evaluation study, conducted in Médecins Sans Frontiéres (MSF) supported health facilities in Malawi, Zimbabwe and the Democratic Republic of Congo.

The evaluation, led by Zibusiso Ndlovu of MSF's Southern Africa Medical Unit in Cape Town, South Africa concluded that Omega's VISITECT® CD4 Advanced Disease lateral flow assay is a promising test for decentralised CD4 screening in resource-limited settings, without access to CD4 testing and it can trigger prompt management of patients with Advanced HIV Disease.

The full research articles can be accessed from the following weblink:

https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0230453&type=printable

Contacts: 

Omega Diagnostics Group PLC	Tel: [phone]
Bill Rhodes, Interim Non-Executive Chairman Colin King, Chief Executive	www.omegadiagnostics.com
Kieron Harbinson, Group Finance Director
finnCap Ltd	Tel: [phone]
Geoff Nash/Hannah Boros (Corporate Finance)
Camille Gochez (ECM)
Walbrook PR Limited	Tel: [phone] or [e-mail]
Paul McManus	Mob: [phone]
Lianne Cawthorne	Mob: [phone]

 

END

 

 

NRAUNAWRRSUSRRR